Evolution of Management and Outcomes in Waldenstr？m Macroglobulinemia: A Population-Based Analysis

DOI: 10.1634/theoncologist.2016-0126

Keywords: Waldenstr？m macroglobulinemia, Rituximab, Bortezomib, Bendamustine, Cost of therapy, Health services research

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text